| Evaluation of achievements in digital transformation across the entire clinical trial lifecycle through AI-based data management and regulatory response technology
| Simultaneously securing clinical trial data reliability and operational efficiency via Maven Clinical Cloud
| Official recognition of digital technology capabilities capable of responding to global regulatory standards
JNPMEDI (CEO Kwon-ho Jung), an innovative company covering the entire bio and clinical lifecycle based on an AI platform, has been selected as a recipient of the ‘Incheon Future Innovation Award’ hosted by Incheon Techno Park. The award ceremony was held during the ‘2025 Incheon Partners Day’ event organized by Incheon Techno Park. This award recognizes the company's achievements in leading the digital transformation of the entire clinical trial lifecycle through its AI-based clinical trial data management and operation platform, as well as its proven commercialization competitiveness.
The ‘Incheon Future Innovation Award’ is a system that selects small and medium-sized enterprises (SMEs) with high future growth potential by comprehensively evaluating technical innovation, market competitiveness, and business model scalability. JNPMEDI received high scores for implementing automation and advancement of clinical trial data management based on AI technology, thereby simultaneously strengthening its capability to respond to domestic and international regulations and its operational efficiency. Taking this award as an opportunity, JNPMEDI plans to further advance its AI-based clinical data automation and regulatory response technologies and accelerate its execution of multi-national clinical trials and entry into global markets.
JNPMEDI’s core solution, ‘Maven Clinical Cloud,’ is an AI-based clinical trial data management and operation platform. It automatically detects errors and abnormal patterns that occur during the data collection and entry process and provides real-time correction guides to researchers. In addition, it supports meeting the submission requirements of major regulatory agencies such as the FDA, EMA, and MFDS by automatically reviewing and refining clinical data and converting it to global clinical data standards such as CDISC (SDTM/ADaM).
Kwon-ho Jung, CEO of JNPMEDI, stated, “The success of a clinical trial depends on data accuracy and regulatory response capabilities.” He added, “We will continue to improve the efficiency and reliability of clinical trials by utilizing AI technology to automate and standardize not only clinical data management but also document preparation and overall regulatory response.”
| Evaluation of achievements in digital transformation across the entire clinical trial lifecycle through AI-based data management and regulatory response technology
| Simultaneously securing clinical trial data reliability and operational efficiency via Maven Clinical Cloud
| Official recognition of digital technology capabilities capable of responding to global regulatory standards
JNPMEDI (CEO Kwon-ho Jung), an innovative company covering the entire bio and clinical lifecycle based on an AI platform, has been selected as a recipient of the ‘Incheon Future Innovation Award’ hosted by Incheon Techno Park. The award ceremony was held during the ‘2025 Incheon Partners Day’ event organized by Incheon Techno Park. This award recognizes the company's achievements in leading the digital transformation of the entire clinical trial lifecycle through its AI-based clinical trial data management and operation platform, as well as its proven commercialization competitiveness.
The ‘Incheon Future Innovation Award’ is a system that selects small and medium-sized enterprises (SMEs) with high future growth potential by comprehensively evaluating technical innovation, market competitiveness, and business model scalability. JNPMEDI received high scores for implementing automation and advancement of clinical trial data management based on AI technology, thereby simultaneously strengthening its capability to respond to domestic and international regulations and its operational efficiency. Taking this award as an opportunity, JNPMEDI plans to further advance its AI-based clinical data automation and regulatory response technologies and accelerate its execution of multi-national clinical trials and entry into global markets.
JNPMEDI’s core solution, ‘Maven Clinical Cloud,’ is an AI-based clinical trial data management and operation platform. It automatically detects errors and abnormal patterns that occur during the data collection and entry process and provides real-time correction guides to researchers. In addition, it supports meeting the submission requirements of major regulatory agencies such as the FDA, EMA, and MFDS by automatically reviewing and refining clinical data and converting it to global clinical data standards such as CDISC (SDTM/ADaM).
Kwon-ho Jung, CEO of JNPMEDI, stated, “The success of a clinical trial depends on data accuracy and regulatory response capabilities.” He added, “We will continue to improve the efficiency and reliability of clinical trials by utilizing AI technology to automate and standardize not only clinical data management but also document preparation and overall regulatory response.”